ACC and AHA release updated cholesterol management guidelines

The American College of Cardiology and American Heart Association have issued new guidelines on cholesterol screening and management, urging earlier testing and personalized risk assessments. The recommendations, presented on March 28 in New Orleans, emphasize lowering LDL cholesterol and incorporating genetic factors like lipoprotein(a). A new risk calculator aims to predict heart disease over longer periods.

The guidelines, the first update since 2018, were published in the Journal of the American College of Cardiology and Circulation. They were unveiled at the American College of Cardiology's 75th Annual Scientific Session in New Orleans. Roger S. Blumenthal, chair of the writing committee and director of the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, stated, 'We know that lower LDL cholesterol levels are better when it comes to reducing the risk of heart attacks, strokes and congestive heart failure.' The guidance stresses lifestyle changes as the foundation, noting that 80% to 90% of cardiovascular disease links to modifiable factors like diet, exercise, and weight control. About one in four U.S. adults has elevated LDL cholesterol, which contributes to atherosclerosis and potential heart events. Doctors are now advised to screen earlier, such as from age 9 for those with familial hypercholesterolemia, and perform a one-time Lp(a) test, which elevates risk by 40% at certain levels. The new PREVENT calculator estimates 10- and 30-year risks starting at age 30, drawing from data on 6.6 million people and including kidney function and blood sugar. Seth Martin, a cardiologist on the committee, said, 'Shifting the paradigm toward proactive prevention strategies earlier in life can meaningfully change the trajectory of cardiovascular disease.' For treatment, optimal LDL targets range from below 100 mg/dL for low-risk individuals to under 55 mg/dL for high-risk ones, with options like statins, ezetimibe, and PCSK9 inhibitors. Risk enhancers such as coronary artery calcium scans and inflammation markers help tailor plans.

Связанные статьи

Illustration depicting projected increases in cardiovascular risks like high blood pressure, obesity, and diabetes among diverse U.S. women by 2050.
Изображение, созданное ИИ

AHA scientific statement projects rising cardiovascular risk factors for U.S. women by 2050

Сообщено ИИ Изображение, созданное ИИ Проверено фактами

A new American Heart Association scientific statement published Feb. 25, 2026 in Circulation projects that cardiovascular risk factors such as high blood pressure, obesity and diabetes will become more common among U.S. women by 2050, with particularly steep increases forecast for some younger women and for several racial and ethnic groups.

Researchers from Mass General Brigham found that the cholesterol drug evolocumab cuts the risk of first-time major cardiovascular events by 31% in high-risk patients with diabetes who lack diagnosed atherosclerosis. The results, from a subgroup analysis of the VESALIUS-CV trial, were presented at the American College of Cardiology's Annual Scientific Session and published in JAMA. Patients on the drug saw LDL cholesterol levels drop significantly alongside standard treatments.

Сообщено ИИ

An experimental oral pill called enlicitide lowered LDL cholesterol by about 60% in a large phase three clinical trial, according to results published in The New England Journal of Medicine. The trial, led by Dr. Ann Marie Navar at UT Southwestern Medical Center and sponsored by Merck, involved 2,909 participants mostly already on statins. If approved, the daily pill could improve access to effective cholesterol treatment.

New research from Turkey shows that men with obesity tend to develop more abdominal fat and liver stress, while women exhibit higher inflammation and cholesterol levels. These findings, presented at the European Congress on Obesity in Istanbul, highlight sex-based differences that could inform personalized treatments. The study analyzed patients treated between 2024 and 2025.

Сообщено ИИ

For decades diabetes diagnosis has depended on blood sugar measurements crossing a set threshold. Researchers now worry this method misses millions of people already developing the disease. Better detection tools are in development to address these shortcomings.

Этот сайт использует куки

Мы используем куки для анализа, чтобы улучшить наш сайт. Прочитайте нашу политику конфиденциальности для дополнительной информации.
Отклонить